Clin2
NCT06846346Possibly a fitRecruiting

Testing Ivonescimab with Chemo for Advanced Stomach Cancer

Metastatic Esophageal AdenocarcinomaAdvanced Esophageal AdenocarcinomaMetastatic Gastric AdenocarcinomaAdvanced Gastric Adenocarcinoma

Treatments studied

Part of Cancer clinical trials.

This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
88 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have advanced or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) that has spread or cannot be removed with surgery.
  • You have not had any prior chemotherapy for advanced disease (unless you have certain tumor markers, then you may have had one prior treatment).
  • You are generally up and active (ECOG performance status 0 or 1).
  • Your blood counts, kidney, and liver function are within healthy ranges.
  • You are not pregnant, breastfeeding, and will use effective birth control if needed.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07070466Recruiting· Phase 2
Ivonescimab with chemotherapy for advanced stomach or esophageal cancer

This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) for people with advanced adenocarcinoma of the esophagus, stomach, or gastroesophageal junction. The drug is designed to help the immune system fight cancer. The study is for people who have not had prior treatment for stage IV disease and whose cancer is HER2 negative.

Santa Monica, California
NCT07374250Not yet recruiting· Phase 2
Perioperative Ivonescimab Plus Chemo for Stomach Cancer

This trial tests a new immunotherapy drug (ivonescimab) given with standard chemotherapy before and after surgery for stomach or gastroesophageal junction cancer. The goal is to see if adding this treatment improves outcomes for patients whose cancer has not spread to other organs.

Chengdu, Sichuan
NCT07385001Recruiting· Phase 1/Phase 2
Ivonescimab with chemotherapy before surgery for esophageal cancer

This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.

Xi'an, Shannxi
NCT06925724Recruiting· Phase 2
Ivonescimab for advanced endometrial or cervical cancer

This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.

Basking Ridge, New Jersey
NCT07686575Recruiting
Ivonescimab with chemo for advanced mouth or throat cancer

This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.

Guangzhou, Guangdong
NCT07244978Not yet recruiting· Phase 2
Immunotherapy plus chemo before surgery for esophageal cancer

This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.

Hangzhou, Zhejiang

Hear when a new Metastatic Esophageal Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.